{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:39:17Z","timestamp":1740177557804,"version":"3.37.3"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100774","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T07:03:49Z","timestamp":1699081429000},"page":"100774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-7195","authenticated-orcid":false,"given":"Niki","family":"Esfahanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Wah Samuel","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna J.","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Catherine","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaleeq","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmugi","family":"Balaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garcia-Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir H.","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalyn","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100774_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101974","article-title":"KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne?","volume":"84","author":"Nagasaka","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"14","key":"10.1016\/j.ctarc.2023.100774_bib0002","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.3390\/jcm11144098","article-title":"Characteristics and treatment outcomes in advanced-stage non-small cell lung cancer patients with a KRAS G12C mutation: a real-world study","volume":"11","author":"Illini","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2023.100774_bib0003","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2020.06.030","article-title":"Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer","volume":"146","author":"Cui","year":"2020","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2023.100774_bib0004","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1078-0432.CCR-20-4023","article-title":"Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2023.100774_bib0005","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics: a 2020 special report on lung cancer; 2020. Accessed July 16, 2023. cancer.ca\/Canadian-Cancer-Statistics-2020-EN."},{"key":"10.1016\/j.ctarc.2023.100774_bib0006","unstructured":"Canadian Partnership Against Cancer. Lung cancer and equity: a focus on income and geography; 2020. Accessed July 16, 2023. partnershipagainstcancer.ca\/lung-equity."},{"issue":"14","key":"10.1016\/j.ctarc.2023.100774_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143572","article-title":"Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ctarc.2023.100774_bib0008","doi-asserted-by":"crossref","first-page":"S1123","DOI":"10.1016\/j.jtho.2021.08.547","article-title":"Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with stable brain metastases: a post-hoc analysis of CodeBreaK 100","volume":"16","author":"Ramalingam","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2023.100774_bib0009","article-title":"A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors","volume":"27","author":"Kartolo","year":"2021","journal-title":"Cancer Treat Res. Commun."},{"key":"10.1016\/j.ctarc.2023.100774_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.026","article-title":"A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease","volume":"159","author":"Spira","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2023.100774_bib0011","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","article-title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non\u2013small-cell lung cancer: the global, multicenter express study","volume":"134","author":"Dietel","year":"2019","journal-title":"Lung Cancer."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100774_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/tlcr-20-958","article-title":"KRASG12C\/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (\u226550 %) lung adenocarcinoma","volume":"10","author":"Frost","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2023.100774_bib0013","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2016.71.2893","article-title":"Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"35","author":"Shepherd","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ctarc.2023.100774_bib0014","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ctarc.2023.100774_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(20)31076-5","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced\/metastatic non\u2013small-cell lung cancer (NSCLC) harboring KRAS G12C mutation","volume":"138","author":"J\u00e4nne","year":"2020","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:23:54Z","timestamp":1722972234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":15,"alternative-id":["S2468294223000965"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100774","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100774"}}